These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 7504102)
1. Microvascular substance P binding to normal and inflamed rat and human synovium. Walsh DA; Salmon M; Mapp PI; Wharton J; Garrett N; Blake DR; Polak JM J Pharmacol Exp Ther; 1993 Nov; 267(2):951-60. PubMed ID: 7504102 [TBL] [Abstract][Full Text] [Related]
2. Differences in the distribution and characteristics of tachykinin NK1 binding sites between human and guinea pig lung. Walsh DA; Salmon M; Featherstone R; Wharton J; Church MK; Polak JM Br J Pharmacol; 1994 Dec; 113(4):1407-15. PubMed ID: 7534186 [TBL] [Abstract][Full Text] [Related]
3. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist. Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347 [TBL] [Abstract][Full Text] [Related]
4. Observations favouring the occurrence of local production and marked effects of bombesin/gastrin-releasing peptide in the synovial tissue of the human knee joint--comparisons with substance P and the NK-1 receptor. Grimsholm O; Rantapää-Dahlqvist S; Dalén T; Forsgren S Neuropeptides; 2008 Apr; 42(2):133-45. PubMed ID: 18289674 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human inflammatory synovitis. Price A; Lockhart JC; Ferrell WR; Gsell W; McLean S; Sturrock RD Arthritis Rheum; 2007 Feb; 56(2):441-7. PubMed ID: 17265479 [TBL] [Abstract][Full Text] [Related]
6. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP kinase. Jeurissen F; Kavelaars A; Korstjens M; Broeke D; Franklin RA; Gelfand EW; Heijnen CJ J Immunol; 1994 Mar; 152(6):2987-94. PubMed ID: 7511635 [TBL] [Abstract][Full Text] [Related]
7. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide. Ciucci A; Palma C; Manzini S; Werge TM Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514 [TBL] [Abstract][Full Text] [Related]
8. Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease. Liu L; Shang F; Markus I; Burcher E J Pharmacol Exp Ther; 2002 Aug; 302(2):627-35. PubMed ID: 12130725 [TBL] [Abstract][Full Text] [Related]
10. Presence of NK1 receptors on a mucosal-like mast cell line, RBL-2H3 cells. Cooke HJ; Fox P; Alferes L; Fox CC; Wolfe SA Can J Physiol Pharmacol; 1998 Feb; 76(2):188-93. PubMed ID: 9635159 [TBL] [Abstract][Full Text] [Related]
11. Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. Rigby M; O'Donnell R; Rupniak NM J Comp Neurol; 2005 Oct; 490(4):335-53. PubMed ID: 16127708 [TBL] [Abstract][Full Text] [Related]
12. Reduced [125I]-Bolton Hunter substance P binding (NK1 receptors) in the basal forebrain nuclei of aged rats. Geraghty DP; Maguire CM Clin Exp Pharmacol Physiol; 2002 Dec; 29(12):1112-5. PubMed ID: 12390300 [TBL] [Abstract][Full Text] [Related]
13. High affinity binding sites for [3H]substance P in urinary bladders of cats with interstitial cystitis. Buffington CA; Wolfe SA J Urol; 1998 Aug; 160(2):605-11. PubMed ID: 9679937 [TBL] [Abstract][Full Text] [Related]
14. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541 [TBL] [Abstract][Full Text] [Related]
15. Localisation and characterisation of substance P binding to human synovial tissue in rheumatoid arthritis. Walsh DA; Mapp PI; Wharton J; Rutherford RA; Kidd BL; Revell PA; Blake DR; Polak JM Ann Rheum Dis; 1992 Mar; 51(3):313-7. PubMed ID: 1374227 [TBL] [Abstract][Full Text] [Related]
16. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1. Nakamura M; Ofuji K; Chikama T; Nishida T Br J Pharmacol; 1997 Feb; 120(4):547-52. PubMed ID: 9051288 [TBL] [Abstract][Full Text] [Related]
17. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Menkes CJ; Renoux M; Laoussadi S; Mauborgne A; Bruxelle J; Cesselin F J Rheumatol; 1993 Apr; 20(4):714-7. PubMed ID: 7684449 [TBL] [Abstract][Full Text] [Related]
18. Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis. Seegers HC; Avery PS; McWilliams DF; Haywood L; Walsh DA FASEB J; 2004 Apr; 18(6):762-4. PubMed ID: 14766794 [TBL] [Abstract][Full Text] [Related]
20. Lower density of synovial nerve fibres positive for calcitonin gene-related peptide relative to substance P in rheumatoid arthritis but not in osteoarthritis. Dirmeier M; Capellino S; Schubert T; Angele P; Anders S; Straub RH Rheumatology (Oxford); 2008 Jan; 47(1):36-40. PubMed ID: 18077488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]